Medtronic Enters Surgical Robotics Arena with Hugo RAS System Securing CE Mark

“# Medtronic's Hugo Surgical Robot Receives CE Mark。”

Surgical robots, also known as medical assistance robots, have seen two medical robotics companies announce plans to go public via SPAC since late 2020, namely Memic and Vicarious Surgical. However, in reality, the number of active players in the surgical robotics sector remains notably limited. This is primarily attributable to two factors: First, like other medical devices, surgical robots must undergo rigorous regulatory review and approval, along with corresponding clinical trials, which significantly extends the development timeline and increases costs; second, the market size for the specific surgical procedures targeted by the robot is a critical consideration. For instance, Memic’s surgical robot Hominis, primarily indicated for hysterectomies, addresses a market size of several billion dollars.

On October 12, 2021, Medtronic's Hugo surgical robot received CE marking approval in Europe. The "CE" mark is a safety certification symbol. Products bearing the "CE" mark can be sold across all European Union member states without needing to comply with individual national requirements, thereby enabling the free movement of goods within the EU. Affixing the "CE" mark to a product signifies that it meets the essential requirements of the EU's "New Approach" directives on technical harmonization and standardization.

Medtronic stated that its products are applicable to urological and gynecological procedures, which account for approximately half of the volume of all robotic surgeries performed today. In other words, once the Hugo system officially enters the market, it will pose a formidable challenge to the entire surgical robotics industry.

On May 27, 2021, the U.S. Food and Drug Administration (FDA) granted an Investigational Device Exemption (IDE) approval to Medtronic’s Hugo robotic system. Without delay, Medtronic completed the first surgery using the Hugo system within 30 days of receiving the approval.

Regarding Medtronic, the company's financial report stated that total revenue for fiscal Q4 2021 reached $8.188 billion, up 37% year-over-year, exceeding Wall Street's previous expectations. Net income for Q4 2021 reached $1.361 billion, a 110% year-over-year increase. The commercial rollout of the Hugo system is poised to drive even more substantial growth for the company.

The development project for the Hugo robotic system was initiated in 2019; however, Hugo encompasses more than just the robot. Medtronic plans to establish a large-scale data platform named Hugo RAS to register clinical data collected globally. Chief Financial Officer Karen Parkhill stated, "Our two biggest opportunities are surgical robotics and renal denervation. We intend to make substantial investments in them to ensure we fully capture a market opportunity worth up to billions of dollars."

Medtronic's entry into surgical robotics will undoubtedly intensify competition in this sector, substantially raising the industry's barrier to entry. However, surgical robotics actually represents a brand-new field, currently primarily focused on wristed instruments and 3D`Visualization`...and surgical video capture technology to assist in surgical procedures, thereby alleviating the frequent shortage of lead surgeons. As industry entry barriers increase, it will, on one hand, restrict the development of other startups in this field, but on the other hand, it may also catalyze the emergence of other types of surgical robots.